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ABSTRACT 
 
In addition to their cell autonomous activities, a number of homeoprotein transcription factors 
transfer between cells and regulate gene transcription, protein translation and chromatin 
organization in a non-cell autonomous way. ENGRAILED-1 homeoprotein is endowed with 
the latter properties and is expressed in spinal cord V1 inhibitory interneurons that synapse on 
large spinal cord -motoneurons. Based on the neuroprotective effects of several 
homeoproteins in the adult central nervous system, we have analyzed the motor phenotype of 
mice lacking one functional Engrailed-1 allele. Engrailed-1 heterozygote mice with 
Engrailed-1 expression reduced by half in the spinal cord start to show muscle weakness, 
abnormal spinal reflex and partial neuromuscular junction denervation between 2 and 3 
months of age. Alpha-motoneuron degeneration is first observed at 4.5 months and progresses 
with time, reaching 50 per cent in 15.5-month-old mice. A single intrathecal injection of 
exogenous recombinant human ENGRAILED-1 at 3 months in the lumbar enlargement 
allows for an addressing of the protein to lumbar -motoneurons and, to a lesser degree, to 
cervical ones. This results in full restoration of strength and extensor reflex for at least 2 
months, in parallel with a preservation of the number of lumbar -motoneurons, and blocks 
endplate denervation. The similarities of the Engrailed-1 heterozygote phenotype to motor 
neuron disease symptoms and the long-lasting effects of a single ENGRAILED-1 injection 
suggests that this approach may be of interest in the search for therapies alleviating the 
consequences of -motoneuron degeneration.  
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INTRODUCTION 
 
Homeoprotein transcription factors are encoded by a class of genes discovered on the basis of 
their developmental functions 1. More recently, it was shown that several of them are also 
expressed in the adult, suggesting that they participate in physiological homeostasis 2,3. 
Similarly to what has been observed during development, adult homeoprotein (HP) functions 
involve both cell autonomous and non-cell autonomous properties 4,5. Non-cell autonomous 
properties arise from the ability of several HPs to transfer between cells due to two highly 
conserved sequences present in their DNA-binding domain or homeodomain 6-9. Examples of 
non-cell autonomous activities in the central nervous system, include the regulation of 
cerebral cortex plasticity and retinal ganglion cell (RGC) survival by OTX2 10-12, the control 
of oligodendrocyte precursor cell and Cajal-Retzius cell migration by PAX6 13,14 and the axon 
guidance activities of ENGRAILED-2 and VAX-1 15-17.  
 
An important ENGRAILED-1 (EN1) function is to ensure the survival of mesencephalic 
dopaminergic (mDA) neurons of the Substantia Nigra pars compacta (SNpc). In En1 
heterozygote (En1-Het) mice, mDA neurons die progressively starting at post-natal week 6 
and only approximately 60% of them remain in one-year-old mice 18. Infusion or injection of 
EN1 or EN2 proteins at the level of the SNpc and their internalization by mDA neurons 
rescues these neurons from degeneration in several Parkinson Disease mouse models 18-20 and 
in a primate model 21. Following a single EN1 injection in mice, mDA rescue lasts for several 
weeks, a long-lasting effect reflecting that EN1, in addition to directly regulating transcription 
and translation 5,22,23, also works as an epigenetic chromatin remodeler 20,24.  
 
In the ventral spinal cord, En-1, but not En2, is expressed in V1 inhibitory interneurons 25-29 
which form inhibitory GABAergic and glycinergic synapses on large α-motoneurons (αMNs) 
30,31 and regulate alternating flexor-extensor activity 28 32. They contribute to the 
excitatory/inhibitory balance with excitatory V0 interneurons and the maintenance of this 
balance may be important for αMN survival 30. 
 
In light of our studies demonstrating that EN1, EN2 and OTX2 have pro-survival activities 5, 
we investigated whether EN1 expressed by V1 interneurons may be important for αMN 
physiology and survival with which they are in synaptic contact. We demonstrate that En1 
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expression is maintained in adulthood and that En1-Het mice have early muscle weakness and 
abnormal spinal reflex associated with partial denervation of the neuromuscular junction 
(NMJ) and a later loss of large αMNs. These degenerative changes are progressive, increasing 
between 2 and 15.5 months of age. A single intrathecal injection of human recombinant EN1 
(hEN1) at 3 months restores muscle strength, normalizes spinal reflex and NMJ innervation 
and promotes survival of αMNs. This restorative and protective activity lasts for at least 2 
months. 
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MATERIALS AND METHODS 
 
Animal Management 
All animals were treated in accordance with the guideline for the care and use of laboratory 
animals (US National Institutes of Health), the European Directive number 86/609 (EEC 
Council for Animal Protection in Experimental Research and Other Scientific Utilization) and 
French authorizations n° 00703.01 “Therapeutic homeoproteins in Parkinson Disease” and n° 
APAFIS #6034-2016071110167703 v2, “Spinal cord motoneurons neuroprotection” delivered 
by the Minister of higher education, research and innovation.  
 
Adult mice were housed two to five per cage and maintained with ad libitum food and water, 
under a 12h light/dark cycle. Transgenic mouse strain En1-Het was bred by the Rodent 
Breeding Services provided by the Animal Care Services at College de France. Colony 
maintenance and genotyping were performed as previously described 33. Both, females and 
males were included in all the studies. 
 
Assessment of disease progression and humane end-point 
Mice were considered for euthanasia if they displayed 15% loss of bodyweight or showed 
signs of paralysis, whichever was reached first. None of the mice were euthanized due to 
these reasons. 
 
Behavioral analyses 
The tests used to evaluate muscle strength and spinal reflexes are forepaw grip strength test, 
inverted grid test and hindlimb extension reflex. Mice were habituated to the behavioral room 
and experimenter 24 hours before the day of testing and again 1 hour before each behavioral 
test. All tests were performed the same day and behavioral assessment was carried by 
evaluators blind to genotype and treatment. Mice were weighed before each session. 
 
Forepaw Grip Strength. The Transducer (IITC Life Science Grip Strength Meter, ALMEMO 
2450 AHLBORN, World Precision Instruments) was calibrated and the scale of the values set 
to grams. During the test, each mouse was lifted by the tail to position the front paws at the 
height as the bar (about 15 cm) and moved towards the bar. Symmetric firm grip with both 
paws was verified and the mouse was pulled backward at a constant speed until the grasp was 
broken and the maximal value was recorded. The test was repeated 5 times per animal with a 
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minimal resting time of 5 minutes between tests and the mean of all values was normalized to 
the weight of each animal. At least 4 mice per group per experiment were used. 
 
Inverted Grid Test. The mouse was placed on a wire grid (15x10 cm) and let to freely explore 
it. After 3-5 minutes, the grid was raised 30 cm above a soft surface and gently turned upside 
down. Latency to falling was recorded three times per mouse with a minimum resting time of 
5 minutes between trials. The longest latency was used for further analysis.  
 
Hindlimb Extensor Reflex. Mice were gently suspended by the tail at a constant height (30 
cm) and scored for hindlimb extension reflex. The scores were assigned from 0 to 3 as 
follows: 3 normal symmetric extension in both hind limbs without visible tremors; 2.5 normal 
extension in both hind limbs with tremor in one or both paws; 2.0 unequal extension of the 
hind limbs without visible tremors; 1.5 unequal extension in the hind limbs with tremors in 
one or both paws, 1.0 extension reflex in only one hindlimb, 0.5 minimum extension of both 
hindlimbs, 0 absence of any hindlimb extension.  
 
Tissue preparation  
Spinal cord. Adult mice were euthanized by an overdose of Dolethal (Pentobarbital, 
Vétoquinol) (1μl/g body weight). The spinal cord was dissected after laminectomy and placed 
in PBS (20mM PO4, 155mM NaCl) to remove the meninges and surrounding connective 
tissue. Cervical and Lumbar enlargements were separated and placed in Paraformaldehyde 
4% (PFA, Thermo Scientific) for 1 hour at room temperature with mild mixing. The tissue 
was then washed in PBS, three times for 30 minutes at room temperature and placed in PBS, 
20% sucrose overnight at 4°C. After cryoprotection, the spinal cords were embedded in 
Tissue Freezing Medium (TFM, Microm Microtech), frozen on dry ice and 30μM sections 
prepared on an HM 560 Microm cryostat (Thermo Scientific).  
  
Muscle. The extraocular (EOM), tongue and lumbrical muscles from the plantar surface of the 
paw were dissected into cold PBS and fixed at room temperature in 4% PFA for 10 minutes 
for extraocular and lumbrical muscles or 1 hour for the tongue. The muscles were then 
washed in PBS and cryoprotected. Extraocular and lumbrical muscles whole-mounts were 
stained to allow for visualization of the entire innervation pattern and detailed analysis of the 
neuromuscular junctions 34. Tongue muscles were embedded and sectioned at 30μm. 
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Cresyl violet staining. Slides with 30μM spinal cord sections were washed in PBS (1X) 3 
times, cleared in O-Xylene (CARLO-HERBA) for 5 minutes, then hydrated in graded 
alcohols with increasing water and placed in Cresyl Violet acetate (MERCK). Sections where 
then dehydrated in increasing alcohols and mounted. 
 
RT-qPCR  
Spinal cords were removed as above and cervical and lumbar enlargements were separated 
and rapidly frozen on dry ice. Total RNA was extracted (RNeasy Mini kit, Qiagen) and 
reverse transcribed using the QuantiTect Reverse Transcription kit (Qiagen). RT-qPCR were 
done using SYBR-Green (Roche Applied Science) and Light Cycler 480 (Roche Applied 
Science). Data were analyzed using the « 2-ddCt » method and values were normalized to 
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh). The following primers were used: 
Engrailed-1 sense: CCTGGGTCTACTGCACACG, antisense: 
CGCTTGTTTTGGAACCAGAT; Gapdh sense: TGACGTGCCGCCTGGAGAAAC, 
antisense: CCGGCATCGAAGGTGGAAGAG 
 
Spinal cord and muscle immunofluorescent labeling. Slides with 30μm spinal cord or muscle 
sections were washed in PBS and permeabilized with 2% Triton. After 30 minutes at RT in 
100μM glycine buffer, sections were blocked in 10% Normal Goat Serum (NGS, Invitrogen) 
or Fetal Bovine Serum (FBS, Gibco) in the presence of 1% Triton and incubated with primary 
antibodies (Sheep anti-Choline Acetyltransferase -ABCAM, 1:1000- or goat anti-Choline 
Acetyltransferase -Millipore, 1:500-, rabbit anti-Engrailed1 -1:300-, mouse anti-neurofilament 
165kDa -DSHB, 1:50- and mouse anti-synaptic vesicle glycoprotein 2A -DSHB, 1:100-) 
overnight at 4°C, washed and further incubated with corresponding secondary antibodies for 2 
hours at room temperature. For muscle staining, -bungarotoxin (Alexa fluor 488 conjugate) 
was used at the same time as the secondary antibodies. Slides were washed and mounted with 
DAPI Fluoromount-G® (Southern Biotech). Controls without primary antibodies were 
systematically included. 
 
Protein production 
Human EN1 (hEN1) was produced as described 11 and endotoxins were removed by Triton X-
144 phase separation 35. In brief, pre-condensed 1% Triton X-144 (Sigma) was added to the 
protein preparation. The solution was incubated 30 minutes at 4°C with constant stirring, 
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transferred to 37°C for 10 minutes and centrifuged at 4000 rpm for 10 minutes at 25°C. The 
endotoxin-free protein was aliquoted and kept at -20°C. 
 
Intrathecal injections 
Mice were anesthetized with ketamine (Imalgene 1000) and xylazine (Rompur 2%) in NaCl 
50mM and placed on the injection platform. The tail of the animal was taken between two 
fingers of one hand and its back was gently flattened with the other hand. The L3 vertebral 
spine was identified by palpation and a 23G x 1" needle (0.6x25mm Terumo tip) was placed 
at the L1 and T13 groove and inserted through the skin at an angle of 20° (Hylden and 
Wilkox, 1980). The needle was slowly advanced forward to the intervertebral space until it 
reached the injection point, provoking a strong tail-flick reflex. Five μl were injected at a rate 
of 1μl/min with or without 1µg recombinant protein. The needle was left in place for two 
minutes after injection and then slowly removed. Animals were placed in a warmed recovery 
chamber until awakening. Extensor reflex and gait analysis were examined 2 and 24 hours 
after injection to ascertain the absence of spinal cord damage. 
 
Image analyses 
Cresyl violet stained spinal cord section images were acquired with a Nikon-i90 microscope 
under bright field conditions at 10x with a Z-stack step of 0.5μm. Immunofluorescence 
stained spinal cord sections images were acquired with a Leica SP5 inverted confocal 
microscope at 20x (Leica DMI6000) and acquisitions of 3D z-stack (0.5μM) were made using 
the UV (405 nm, 50mW), Argon (488 nm, 200mW) and DPSS (561 nm, 15mW) lasers. For 
MN quantification, at least five spinal cord sections separated by > 900μm were analyzed for 
each animal. ChAT+ cells and Cresyl stained cells with a cell soma area greater than 100μm2 
were manually outlined using ImageJ software (NIH, Bethesda, MD) and their area 
determined. Analyses were carried out on Z-stacks through the entire 30μm thickness of the 
section. Cells were classified as small (100-199m2 cross sectional area), intermediate 
(between 200-299 μm2) and large (greater than 300μm2). 
 
Lumbrical, EOM and tongue muscles were imaged with a Leica SP5 inverted confocal 
microscope (Leica DMI6000) with a motorized XY stage. 3D z-stack (0.5μM) acquisitions 
were made as indicated above (UV, Argon and DPSS) and images analyzed using ImageJ 
software. Analyses were performed blind to the genotype and treatment. Endplates where 
categorized as fully innervated (neurofilament overlying more than 80% of the endplate), 
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partially innervated (neurofilament overlying up to 80% of the endplate) or denervated (no 
neurofilament overlying the endplate) 36. Endplate morphology was evaluated by counting the 
number of endplates with perforations (areas lacking α-bungarotoxin staining). For 
postsynaptic analysis, each endplate was manually outlined using ImageJ software and area 
calculated. All analyses were done on the entire Z-stacks through the NMJ. 
 
Statistical analyses 
Results are based on seven independent experiments. Muscle weakness and abnormal reflex 
score in 3-month-old En1-Het mice was observed in 6-7 of the 7 experiments, NMJ 
denervation in 5 of 5 experiments and MN loss in 4 of 4. The restoration of muscle strength 
and normalization of the spinal reflex after hEN1 injection was observed in 5 of 5 
experiments and a significant increase in MN survival in 4 of 4 experiments. 
Data are expressed as mean ± SD unless otherwise indicated. Statistical significance was 
determined as indicated. For RT-qPCR, WT and En1-Het mice were compared by Unpaired 
T-test with equal SD. For behavioral and NMJ analyses and MN counting in the time-course 
study, groups were compared by Unpaired T-test with equal SD comparing WT with En1-Het 
for each time point. For the intrathecal injections, behavioral and NMJ analyses and MN 
counting, experimental data were compared by one-way ANOVA followed by a post hoc 
Dunnett’s test for comparisons to WT. For behavioral analysis in the time-course protection 
of injected hEN1, groups were compared by Unpaired T-test with equal variances comparing 
WT with En1-Het injected at each time point. For behavioral analysis in the time-course 
protection experiment following the injection of hEN1 in 9-month-old mice and of the hEN1 
mutant hEN1Q50A, groups were compared by One-Way-ANOVA with Tukey's multiple 
comparisons test comparing the groups for each time point.  
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RESULTS 
 
En1-Het mice show early and progressive motor deficits 
Previous studies reported En1 expression in V1 interneurons in the early postnatal mouse 
spinal cord 29. We verified that this expression is maintained at the same levels throughout life 
and is decreased by twofold in the En1-Het mouse both at 4.5 and 16 months, thus during the 
time frame of all experiments (Fig. 1a, b). This indicates that V1 interneurons survival is 
preserved in the En1-Het mice, in contrast with the situation for mDA neurons of the SNpc 18. 
En1-Het mice display the same average weight gain as their WT littermates at all ages studied 
(Fig. 1c). For the three tests used to assess muscle strength, WT and En1-Het animals evolved 
differently, the latter showing signs of loss of strength compared to their WT littermates (Fig. 
1d-f). At one and two months of age forepaw grip strength was similar in En1-Het and WT 
mice, but a significant reduction was first measurable at 3 months that persisted through 15.5 
months of age (Fig. 1d). The inverted grid test assesses the ability of the four limbs to resist 
gravity. Two-month-old En1-Het mice resisted significantly less than WT mice and holding 
time further diminished between two months and 15.5 months, revealing a progressive loss of 
strength (Fig. 1e). Finally, the hind limb extensor reflex was taken to monitor purely spinal 
function. WT mice had an extensor score of about three at all ages but the score of the En1-
Het animals started to deteriorate overtime between 2 and 15.5 months (Fig. 1f). Taken 
together, these results show that En1-Het mice have a progressive loss of muscle strength and 
a deteriorating spinal reflex compared to WT siblings. 
 
Presynaptic pathology in the neuromuscular junction of the lumbrical muscles in En1-
Het mice  
Motor deficits are often accompanied by early synaptic changes at the NMJ, a specialized 
synapse between MN axon terminals and skeletal muscle fibers. Since NMJs are highly 
vulnerable from very early stages of motor disorders, we analyzed the NMJ morphology and 
synaptic characteristics of three muscle groups with different degrees of vulnerability in 
neuromuscular diseases 36. Data corresponding to lumbrical endplates are described in Figure 
2 and those corresponding to extraocular and tongue muscles in Supplemental Figure 1.  
 
Alpha-bungarotoxin and antibodies against neurofilament and synaptic vesicle protein 2A 
were used in combination to visualize acetylcholine receptor (AChR) clusters of the motor 
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endplate and motor axon terminals, respectively (Fig. 2a). The typical endplate morphology 
well centered on the lumbrical muscle fibers was observed in all mice examined 34. No 
changes were found in the average number of AChR clusters between WT and En1-Het mice 
(Fig. 2b). The area of the motor endplate did not differ between WT and En1-Het mice 
throughout 9 months of age, and is significantly reduced in En1-Het mice at 15.5 months of 
age (Fig. 2c). Endplate perforations (post-junctional folds) are a region of the endplate devoid 
of AChR. Their number reflects the state of maturation of the NMJ and normal healthy 
muscles show a complex morphology with multiple perforations 37. The percentage of 
endplates with perforations shows no difference between WT and En1-Het mice throughout 9 
months of age (Fig. 2d) but is significantly reduced in the En1-Het mice at 15.5 months of 
age. Finally, the lumbrical NMJ innervation was evaluated. Motor endplates where 
categorized as fully innervated if neurofilament immunoreactivity overlaid more than 80% of 
the endplate. Figure 2e shows the significantly reduced NMJ innervation in En1-Het mice, 
starting at 3 months and worsening with age.   
 
In contrast with lumbrical endplates, no differences between the two genotypes were observed 
in any of the NMJ morphological characteristics for extraocular and tongue muscles, at any 
age (Supp. Fig 1).  
 
Loss of large αMN in the En1-Het mouse spinal cord 
The progressive muscle weakness of the En1-Het is paralleled with a partial denervation of 
the muscle fibers possibly reflecting αMN loss. We thus analyzed the number of neurons 
present in the cervical and lumbar enlargements of the spinal cord in the En1-Het mice and 
their WT littermates. At 15.5 months, the total number of Cresyl-stained neurons in the 
ventral spinal cord was similar for the cervical (Supp. Fig 2) and lumbar enlargements at 15.5 
months (Fig. 3a,b). In contrast, a decrease in the number of large densely stained cells was 
clearly apparent in the En1-Het mouse spinal cord. To understand this, the neurons were 
classified according to their surface: small neurons of 100-199μm2, intermediate size neurons 
of 200-299μm2, and large neurons 300μm2 or more. The number of small and intermediate 
size neurons remained constant at all ages, with no difference between En1-Het and WT mice 
(Fig. 3c, d) while the number of large neurons decreased progressively between months 4.5 (≈ 
20% loss) and 15.5 (≈ 50% loss) in En1-Het animals (Fig. 3e).  
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Choline Acetyltransferase (ChAT) is selectively expressed in γ and αMNs that can be 
distinguished on the basis of size 38. In order to better identify the neurons that are lost in the 
ventral spinal cord of En1-Het animals we used ChAT immunoreactivity in 9-month-old 
mice. Compared to WT, Figure 4a clearly shows a loss of large ChAT+ cells in the En1-Het 
spinal cord and Figure 4b-c which compares Cresyl violet and ChAT staining for medium size 
and large neurons, confirms that the cells that disappear in the En1-Het mutant are αMNs. It is 
of note that the loss of large αMNs in the En1-Het mouse spinal cord is not accompanied by a 
corresponding increase in the intermediate size class of MNs, precluding αMN shrinkage.  
 
Taken together, these results show that, compared to WT, En1-Het mice present a loss of 
large αMNs in the ventral spinal cord that is first apparent at 4.5 months and progresses with 
time, reaching about 50% at 15.5 months of age. 
 
Recombinant hEN1 reverses the En1-Het motor phenotype, restores NMJ morphology 
and reduces αMN loss 
Previously, we showed that exogenous HP transcription factors, including EN1, EN2 and 
OTX2, rescue mDA neurons and RGCs from an in vivo stress 11,19,20 and that this survival 
effect holds for several weeks following a single HP injection 11 20. This led us to test whether 
a single intrathecal hEN1 injection into the spinal cord of En1-Het mice could have total or 
partial rescuing activities on any of the analyzed phenotypes. In the En1-Het mice muscle 
weakness and abnormal extensor reflex appear between 2 and 3 months (Fig. 1) while αMN 
loss is only visible at 4.5 months (Fig. 3e), suggesting that three months of age is a valuable 
“therapeutic” window. One μg of hEN1 was injected and 24h later strong EN1 
immunofluorescence was detected in the perivascular space and in neurons of lumbar spinal 
and cervical cord (Fig. 5a, b). ChAT immunofluorescence showed that many of the cells that 
internalized hEN1 are large-sized αMNs and that the number of hEN1-stained cells was much 
lower in the cervical region probably due to its distance from the lumbar injection site (Fig. 
5b). 
 
Three-month-old En1-Het and WT mice were evaluated for muscle weakness and hindlimb 
extensor reflex and, 2 days later, En1-Het mice were separated into two groups. A first group 
received 5μl of vehicle and the other 1μg of hEN1 in 5μl of vehicle without incidence on 
weight (Fig. 5c). As already shown, before intrathecal injections, En1-Het mice (compared to 
WT siblings) had reduced forepaw grip strength, reduced time holding onto the inverted grid 
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and had a slightly lower hind limb reflex score (Fig. 5d-f). One month and a half later, En1-
Het mice treated with vehicle continued to do worse than WT mice in the three tests whereas 
the performance of hEN1 injected mice were undistinguishable from those of WT controls 
(Fig. 5d-f). Synapse morphology and αMN death were analyzed in the 4.5-old-mice injected 
at 3 months with vehicle or hEN1. The percentage of fully occupied endplates, reduced in 
En1-Het mice (Fig. 2), returns to normal in hEN1 treated animals (Fig. 6a). At 3 months of 
age, En1-Het mice have a normal number of αMNs characterized by size and ChAT staining, 
but some loss has already occurred 1.5 months later (Fig. 3e). Figure 6 (b, c) illustrates that 
the number of Cresyl-stained large cells and ChAT-stained large cells at the lumbar 
enlargement is identical at 4.5 months between WT mice and En1-Het siblings injected with 
hEN1 at month 3.  
 
As a control, a mutant of hEN1 (hEN1Q50A) in which glutamine in position 50 of the 
homeodomain was mutated into alanine, thus allowing internalization but preventing high 
affinity binding to DNA 39 was also injected but showed no rescuing activity (Supp. Fig 3).
  
 
Taken together, these experiments demonstrate that a single hEN1 injection at month 3 and at 
the lumbar level restores muscle strength, normalizes the spinal reflex and restores a normal 
NMJ morphology. In addition, the treatment blocks lumbar, but not cervical αMN 
degeneration, for a period of at least 1.5 months (Supp. Fig 4). That En1-Het mouse muscle 
strength is restored in the forepaw grip strength and inverted grid tests suggests that the 
surviving αMNs in the cervical enlargement have benefited from hEN1 injection.  
 
A single hEN1 injection at 3 months of has long-lasting effects on En1-Het mice and no 
effect at 9 months  
To investigate if the rescue effect of a single hEN1 injection in three-month-old En1-Het mice 
could last more than 1.5 months, 1μg of hEN1 was injected in three-month-old En1-Het mice 
that were assessed weekly during the first month following injection and then monthly up to 
six months. Before injection, three-month-old En1-Het mice showed significant muscle 
weakness and an abnormal reflex compared to WT mice (Fig. 7a-c). One week after injection 
the forepaw grip strength and the extensor reflex in the En1-Het mice were normalized to WT 
values. This improvement was fully maintained for 3 months, after which performance 
declined progressively to reach pre-injection levels. The improvement in the inverted grid test 
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was more modest but followed a similar time course. When compared to 9-month-old 
untreated En1-Het mice, mice injected with hEN1 at 3 months and kept for 6 months did not 
maintain wild type values but performed better in the 3 tests than untreated age-matched En1-
Het mice. At the end of the study, muscles and spinal cord tissue were dissected and analyzed. 
Figure 8 shows that En1-Het mice treated with hEN1 show higher NMJ innervation at 9 
months than untreated age-matched En1-Het mice, although less than WT littermates (Fig. 
8a). A similar partial rescue at 9 months was also observed for  survival (Fig. 8b). These 
results suggest that a single injection of hEN1 slows the degenerative processes that normally 
occur in the En1-Het mice. 
 
To examine whether late administration of hEN1 would have positive effects on the En1-Het 
phenotype, 1μg of hEN1 or vehicle was injected in 9-month-old En1-Het mice. Before 
injection, En1-Het mice manifested significant reductions in forepaw grip strength, time of 
holding onto the inverted grid and extensor reflex score (Fig. 7d-f). Compared to WT siblings, 
vehicle and hEN1-injected En1-Het mice continued to be significantly impaired in the three 
tests, although, one may notice a very small improvement of the hEN1-treated En1-Het mice, 
two months post injection, for the forepaw grip strength and extensor reflex tests. At the end 
of the experiment the now 15.5-month-old mice were dissected to analyze NMJ occupancy 
and count the surviving MNs. As shown in Figure 8c-d, injection after 9 months had no 
effect on either morphological criteria evaluated at the lumbar enlargement or for hindlimb 
muscles. 
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DISCUSSION 
 
This study establishes the importance of EN1 expression in  survival and motor strength. 
It also shows that one intrathecal injection of hEN1 can rescue the En1-Het phenotype with a 
long-lasting activity when the injection is made before degeneration has reached a no-return 
point, as in 9-month-old En1-Het mice. In this study, we used the human recombinant protein, 
but the human and mouse proteins are 91.1% identical and were used with the same efficiency 
in mDA neuron survival experiments 19-21,24.  
 
A day after injection hEN1 is present around vascular structures probably in the perivascular 
space from which it penetrates into the parenchyma and reaches the cell interior. Indeed, it 
has been shown before that EN1 and EN2, similarly to many HPs 5,9 translocate across the 
plasma membrane to reach the cell cytoplasm through a mechanism distinct of endocytosis 8. 
The examination of the ventral horns suggests a preferential accumulation in neurons, not 
precluding the possibility that other cells types, in particular astrocytes, also capture the 
protein. Among the neurons, the large neurons with a morphology evoking  are 
systematically more strongly labeled than the medium and small size ones. Although this 
requires a more detailed study, it might reveal that, physiologically, EN1 expressed by the V1 
neurons is secreted and internalized by s expressing EN1-binding sites. 
 
The latter hypothesis is in line with what was demonstrated in the case of OTX2, a HP which 
is specifically recognized in the cerebral cortex by a class of interneurons expressing 
parvalbumin 10. OTX2 internalization is due to its recognition by glycosaminoglycans (GAG) 
present at the surface of these interneurons thanks to the GAG binding domain 
(RKQRRERTTFTRAQL) overlapping with the first helix of the homeodomain 40. 
Interestingly, similar GAG-binding domains are present upstream of the homeodomain in 
many HPs 3,5, including EN1 and EN2 for which this putative GAG-binding sequence is 
KEDKRPRTAFTAEQL. The potential role of this domain in the specific targeting of EN1 
and the presence of EN1 binding sites at the  surface will be investigated in further 
studies.  
 
A striking observation is that, in the En1-Het mouse, the extensor reflex score is reduced at 2 
months and muscle strength between 2 and 3 months. This corresponds to the decrease in 
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fully occupied endplates first observed at 3 months and this precedes the loss of 
s observed at 4.5 months. This slight temporal discrepancy probably reflects that the 
s are experiencing retrograde degeneration with the terminals, thus strength, affected 
before cell body loss. This replicates what occurs in En1-expressing mDA neurons in the 
same En1-Het mouse line: their terminals show degeneration signs at 4 weeks, whereas the 
neurons only start dying at 6weeks of age 18,41. In this context, it is important to note that 
hEN1 injection at 3 months not only prevents  death for weeks, but also restores normal 
endplate morphology and muscle strength. This suggests that the neurodegenerative process is 
slowed or halted at least for a limited period of time since no recovery is possible after 9 
months. This time limit is interesting as the time course of  degeneration is very slow 
with 40% of the cells still alive at 15.5 months and seems to reach a plateau. It is thus possible 
that s are heterogeneous in term of their dependency to EN1. This is reminiscent of the 
SNpc and Ventral Tegmental Area (VTA) mDA neurons, the two populations expressing En1, 
but the latter being more resistant to En1 hypomorphism 18. It is also interesting to note that 
forelimb muscle strength was restored suggesting that even the low levels of hEN1 that attain 
cervical spinal cord have beneficial effects on the remaining MNs.      
 
Homeoproteins can act cell and non-cell autonomously and this raises two possible 
mechanisms leading to the phenotype observed in the En1-Het mice and protection by 
exogenous hEN1. A direct cell autonomous effect would mean that spinal V1 interneurons are 
dysfunctional in the En1-Het mouse. Since these cells are an essential component of the 
reciprocal inhibitory MN circuit, loss of their inhibitory input places MNs at risk for 
degeneration 42. Deficits in inhibitory interneurons in the spinal cord of motor neuron disease 
models have been reported 43 and in particular Renshaw cell pathology has also been observed 
following MN loss 44. Alternatively, but not mutually exclusive, EN1 might act in a non-cell 
autonomous fashion. Such non-cell autonomous activities can be of several sorts. Firstly, EN1 
may regulate within spinal V1 interneurons the expression of classical trophic factors that 
support, following their secretion,  survival. Secondly, EN1 might be secreted and 
internalized by intermediate cell types, such as astrocytes or microglial cells, enhancing their 
MN-directed trophic activity 45,46. Finally, V1 interneurons may provide EN1 to αMNs 
where the protein would exert its direct protective activity as observed for OTX2 in RGCs 11. 
It is possible that EN1 protects the MNs that internalize it through one or several of the 
EN1-controled mechanisms that protect mDA neurons of the SNpc from oxidative stress 20,21. 
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Among these mechanisms are the regulation, through local protein translation, of Complex I 
mitochondrial activity 19, DNA break repair, heterochromatin maintenance and the repression 
of long interspersed nuclear elements (LINE-1) expression 20,24. The evaluation of these 
possibilities will be the object of future studies. 
 
The En1-Het mouse presents muscle weaknesses, abnormal spinal reflex, NMJ denervation 
and αMN loss, all phenotypes highly reminiscent of changes in Amyotrophic Lateral Sclerosis 
(ALS) patients and in many ALS mouse models. This raises the question as to whether the 
results reported here are relevant for motor neuron diseases. It is important to note that En1-
Het mice do not present a number of important symptoms such as weight loss, respiratory 
distress, and complete paralysis or endpoint death. The absence of weight loss in the En1-Het 
mice may be an effect of the Swiss background mouse line. In contrast to virtually all mouse 
lines whose body weight asymptotes in mid-adulthood (Jackson Laboratory; 
https://www.jax.org/#) both the En1-Het mice and their WT littermates continue to gain 
weight reaching about 80 grams at 2 years of age. Thus, it is possible that metabolic defects 
specific to this genetic background may mask weight losses due to αMN degeneration.  
 
It is also possible that the extensive αMN loss up to about 60% at 15.5 months of age has little 
or no impact on feeding motor behaviors, although this is difficult to reconcile with the severe 
phenotypes observed in mouse models of ALS. ALS patients and mice in some ALS models 
have respiratory or cardiac failure 47-49. We did not observe any obvious breathing difficulty 
in the En1-Het mice and the long-life span of the mice (at least up to two years thus far) 
indicates no cardiac failure. The phrenic αMNs that drive respiration are concentrated at the 
C3-C4 level in mice 45. Thus, interneuron inhibition on phrenic αMNs or αMNs themselves 
may be insensitive to reduced EN1. At the thoracic level that provides cardiac modulation 
47,50,51, inhibitory Ia interneurons are absent 52. We did not assess the number or phrenic αMN 
in the thoracic spinal cord. It would be interesting to determine if the absence of phrenic and 
thoracic αMN loss correlates with the absence of breathing difficulties or cardiac function. 
With regards to ALS patients, since all αMNs derive from the same lineage and transcription 
factor program, it is possible that phrenic and thoracic αMNs might respond to exogenous 
hEN1. 
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FIGURE LEGENDS 
 
Figure 1. En1-Het mice show progressive muscle weakness and abnormal spinal reflex 
 RT-qPCR of the lumbar enlargement of 4.5 (a) and 16 (b) month-old En1-Het mice and WT 
littermates shows the stable expression of En1 in the WT at both ages and its reduced 
expression in heterozygous mice. c) There are no differences in body weight between En1-
Het mice and WT littermates. d) En1-Het mice show reduced normalized grip strength at 3 
months of age with increase weakening with age, compared to WT. e) En1-Het mice hold 
onto the inverted grid less time compared to WT mice starting at two months of age. f) En1-
Het mice start to show an abnormal hind limb reflex score at two months of age and this 
worsens with age. WT littermates show a normal score at all ages. Comparisons by Unpaired 
T-test with equal SD comparing WT with En1-Het at each time point (*p<0.05; **p<0.005; 
***p<0.0005; ****p<0.0001). 
 
Figure 2. En1-Het mice develop NMJ abnormalities  
a) Confocal micrographs of representative images of lumbrical muscle neuromuscular 
junctions in of the WT and En1-Het mice at 3 months of age stained for 2H3/SV2 (red) and α-
BTX (green). b) NMJs of En1-Het and WT mice do not differ in the number of AChR 
clusters. c) NMJ endplate area is reduced in the En1-Het mice at 15.5 months of age. d) The 
maturation state of the endplates as reflected in the percentage of endplates with perforations 
is similar in the two genotypes through 9 months of age, but a difference appears at 15.5 
months, with a reduction in the percentage with perforations in the En1-Het mouse. e) En1-
Het mice show a significant decrease in the percentage of fully occupied endplates starting at 
three months of age and this percentage declines with age compared to WT mice. Scale bar: 
100μm applies to all; Comparisons made by Unpaired T-test with equal SD comparing WT 
with EN1-Het (*p<0.05; **p<0.005; ***p<0.0005; ****p<0.0001).  
 
Figure 3. Specific loss of large αMNs in lumbar spinal cord of En1-Het mice 
a) Representative light field micrographs of the left ventral horn of the lumbar enlargement of 
a WT and an En1-Het mouse at 15.5 months of age, stained with Cresyl violet (arrows point 
to large cells). b-d) No differences between En1-Het and WT mice were observed for the 
number of all Cresyl-stained cells, the number of small stained cells nor for the number of 
medium stained cells. e) A significant reduction in the number of large neurons in the En1-
Het mice, first seen at 4.5 months of age increases with time with a nearly 50% loss in 15.5-
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month-old En1-Het mice, compared to WT littermates. Scale bar: 100μm; Comparisons made 
by Unpaired T-test with equal SD comparing WT with En1-Het mice (*p<0.05; **p<0.005; 
***p<0.0005; ****p<0.0001). 
 
Figure 4. The large MN are ChAT-positive αMNs 
a) Representative confocal micrographs of the left ventral horn of the lumbar enlargement of 
the WT and En1-Het mice at 9 months of age stained for ChAT (Green). b) The number of 
ChAT+ cell between 200 and 299μm2 (putative γMNs) is maintained between genotypes. c) 
En1-Het mice show a reduction of ChAT+ cells with cross-sectional areas > 300μm2 (putative 
αMNs). Scale bar: 100μm; Comparisons made by Unpaired T-test with equal SD comparing 
WT with En1-Het mice (*p<0.05; **p<0.005; ***p<0.0005; ****p<0.0001). 
 
Figure 5. Intrathecal hEN1 penetrates the spinal cord parenchyma and reverses the 
En1-Het motor phenotype  
a) Representative confocal micrographs of the lumbar enlargement stained for ChAT (Green) 
and EN1 (Red) in a WT mouse 24 hours after intrathecal injection of 1μg of hEN1. Arrows 
show examples of hEN1 internalized by numerous cells. Arrowheads show examples of hEN1 
in and/or around vessels. b) Inset of the right ventral horn cervical enlargement showing that 
hEN1 injected at the lumbar level can reach ChAT-positive cells (arrows) in the cervical 
region. c) There are no differences in body weight before and after injection. d) Before hEN1 
injection, En1-Het mice have reduced forepaw grip strength and hEN1 injection at 3 months 
of age restores normal strength in 4.5-month-old En1-Het mice. e) Before hEN1 treatment, 
En1-Het mice hold onto the inverted grid less time that WT littermates and hEN1 injection at 
3 months of age restores normal strength in 4.5-month-old En1-Het mice. f) En1-Het mice 
show an abnormal hind limb extensor score compared to WT and hEN1 injection at 3 months 
of age restores normal scores in 4.5-month-old En1-Het mice. Scale bar: 500μm. 
Comparisons made by Unpaired T-test with equal SD (*p<0.05; **p<0.005; ***p<0.0005; 
****p<0.0001). 
 
Figure 6. Intrathecal hEN1 preserves NMJ innervation and promotes  survival 
a) En1-Het mice treated with vehicle show a significant reduction in the number of endplates 
that are fully innervated; those treated with hEN1 have a percentage of fully occupied 
endplates similar to that found for in WT mice. b) Vehicle-treated En1-Het mice show a 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/734020doi: bioRxiv preprint first posted online Aug. 13, 2019; 
 20 
significant loss of large neurons stained with Cresyl violet while those treated with hEN1 
show a complete protection against loss. c) Vehicle-treated En1-Het mice show a significant 
loss of large ChAT+ MNs, while En1-Het mice treated with hEN1 show complete 
protection. Comparisons made by Unpaired T-test with equal SD (*p<0.05; **p<0.005; 
***p<0.0005; ****p<0.0001). 
 
Figure 7. A single dose of hEN1 injected at 3 months of age, but not at 9 months, has a 
long-lasting effect on En1-Het mice behavior  
a) Before hEN1 injection En1-Het mice have reduced weight normalized grip strength but 
within one week after hEN1 injection the mice have normal or near normal forepaw grip 
strength. This improvement lasts up to three months. Note that the forepaw grip strength in 
nine-month-old hEN1-treated En1-Het mice is slightly better than in age-matched non-treated 
En1-Het mice (open square). b) Before hEN1 injection En1-Het mice held onto the inverted 
grid for shorter times that WT mice. After hEN1 the time holding onto the grid improved 
somewhat up to three months after injection and then declined. The time holding onto the grid 
by 9-month-old hEN1-treated En1-Het mice is significantly improved compared to age-
matched non-treated En1-Het mice (open square) c) Three-month-old En1-Het mice have an 
abnormal hind limb extensor reflex compared to WT mice. Within one week after hEN1 the 
extensor score is normalized to the WT score, remains normal up to two months and then 
declines. At the end of the experiment the extensor score of 9-month-old hEN1-treated En1-
Het mice is significantly better than in age-matched non-treated En1-Het mice (open square). 
d-f) Nine-month-old En1-Het mice performed worse than WT mice in the three tests. 
Intrathecal hEN1 injection at 9 months of age did not improve performance over the next six 
and a half months compared to non-treated littermates.  
 
Figure 8. A single dose of hEN1 injected at 3 months of age, but not at 9 months, has a 
partial protective effect on NMJ morphology and  survival 
a) In 9-month-old En1-Het mice treated with hEN1 the percentage of fully occupied endplates 
was significantly reduced compared to WT mice, but significantly greater that in 9-month-old 
non-treated En1-Het mice. b) In 9-month-old hEN1-treated En1-Het mice the number of 
s in the lumbar spinal cord was less than in WT mice but significantly higher than on 
age-matched non-treated En1-Het mice. c,d) Fifteen and a half month old En1-Het mice 
treated with hEN1 at 9 months of age showed no improvement in fully occupied endplates or 
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 survival compared to untreated En1-Het mice. (*p<0.05; **p<0.005; ***p<0.0005; 
****p<0.0001). 
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